Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.
The following table provides information about the project.
VECTORIOUS MEDICAL TECHNOLOGIES LTD
|Coordinator Country||Israel [IL]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
|Duration (year-month-day)||from 2017-05-01 to 2017-09-30|
Take a look of project's partnership.
|1||VECTORIOUS MEDICAL TECHNOLOGIES LTD||IL (TEL AVIV JAFFA)||coordinator||50˙000.00|
Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed trough a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/ red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes. During Phase 1 project the Company will assess scale-up industrialization plan, product development and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.
In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise SoftwareRead More
Osmotic Wearable Bolus Injector (oWBI) for viscous drug deliveryRead More
A 1Gpixel Camera to Open the Markets of Aerial Data AcquisitionRead More